faculty of Dentistry, Fayoum University
Fayoum, Alexandria Governorate, 21523, Egypt
Location status: Recruiting
NCT Number: NCT06762210
Smoking cessation remains a significant public health challenge, with millions of individuals struggling to quit despite available interventions.
Interested in participating?
Request Info21 year–65 year
All sexes
Interventional
Not applicable
Fayoum, Alexandria Governorate, 21523, Egypt
Location status: Recruiting
Oral health deterioration is a well-documented consequence of smoking, including periodontal disease, tooth discoloration, and oral cancer. Recent advancements in artificial intelligence (AI) have led to the development of AI Molar Mind, a digital tool designed to assess oral health and provide personalized feedback to motivate behavioral change. This study aims to evaluate the efficacy of AI Molar Mind in aiding smoking cessation by leveraging oral health evaluations as a motivational tool.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
a baseline oral health assessment using AI Molar Mind, which analyzes intraoral images and self-reported oral health data.
Time frame: base line, 6-month post smoking cessation
Biochemically verified smoking cessation at 6 months (measured by exhaled carbon monoxide levels <6 ppm).
Contact information is provided by the study sponsor or research team.
Fayoum University
Other
the Effectiveness of AI Molar Mind for Smoking Cessation Through Dental Health Evaluation: Randomized Control Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06883097
Acquired Immunodeficiency Syndrome, Behavior
Winston-Salem, North Carolina, United States
View Trial DetailsNCT06901713
Behavior, Chemically-Induced Disorders
Hangzhou, China
View Trial DetailsNCT06862050
Behavior, Chemically-Induced Disorders
Augusta, Georgia, United States
View Trial DetailsNCT07030387
Behavior, Chemically-Induced Disorders
Efeler, Aydın, Turkey (Türkiye)
View Trial Details